Your browser doesn't support javascript.
loading
Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
Butler, Karin; Anderson, Sarah-Jane; Hayward, Olivia; Jacob, Ian; Punekar, Yogesh Suresh; Evitt, Lee Alexandra; Oglesby, Alan.
Affiliation
  • Butler K; Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom.
  • Anderson SJ; GlaxoSmithKline, Brentford, United Kingdom.
  • Hayward O; Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom.
  • Jacob I; Health Economics & Outcomes Research Ltd, Cardiff, United Kingdom.
  • Punekar YS; ViiV Healthcare, Brentford, United Kingdom.
  • Evitt LA; ViiV Healthcare, Brentford, United Kingdom.
  • Oglesby A; ViiV Healthcare, NC.
J Manag Care Spec Pharm ; 27(7): 891-903, 2021 Jul.
Article in En | MEDLINE | ID: mdl-34185564

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / HIV-1 / Lamivudine / Heterocyclic Compounds, 3-Ring Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Manag Care Spec Pharm Year: 2021 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / HIV-1 / Lamivudine / Heterocyclic Compounds, 3-Ring Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Manag Care Spec Pharm Year: 2021 Document type: Article Affiliation country: Country of publication: